Sulfadiazine, Silver
Silver sulfadiazine is a topical antimicrobial compound combining silver ions and sulfadiazine that acts through dual mechanisms: silver ions denature bacterial DNA and disrupt bacterial cell membranes, while sulfadiazine inhibits dihydropteroate synthase to block folate synthesis, providing broad-spectrum activity including Pseudomonas aeruginosa. It is used extensively for prevention and treatment of wound infection in partial and full-thickness burn injuries. The sustained release of silver ions from the cream provides prolonged antimicrobial activity at the wound surface.
分子量
357.1400 g/mol
TPSA
95.30 Ų
作用机制
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
二维结构
Cite this structure
Embed this structure
SMILES
Nc1ccc(S(=O)(=O)[N-]c2ncccn2)cc1.[Ag+]
InChI
InChI=1S/C10H9N4O2S.Ag/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10;/h1-7H,11H2;/q-1;+1
Molecular Formula
C10H9AgN4O2S
HBD / HBA
1 / 6
可旋转键数
3
重原子数
18
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
常见问题
Silver sulfadiazine is a topical antimicrobial compound combining silver ions and sulfadiazine that acts through dual mechanisms: silver ions denature bacterial DNA and disrupt bacterial cell membranes, while sulfadiazine inhibits dihydropteroate synthase to block folate synthesis, providing broad-spectrum activity including Pseudomonas aeruginosa. It is used extensively for prevention and treatment of wound infection in partial and full-thickness burn injuries. The sustained release of silver ions from the cream provides prolonged antimicrobial activity at the wound surface.
Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.
Yes, Sulfadiazine, Silver is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1382627. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 441244. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="sulfadiazine-silver"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/sulfadiazine-silver/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/sulfadiazine-silver/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/sulfadiazine-silver/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="sulfadiazine-silver"></drugfyi-drug>